These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22441643)

  • 1. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway.
    Burger EA; Ortendahl JD; Sy S; Kristiansen IS; Kim JJ
    Br J Cancer; 2012 Apr; 106(9):1571-8. PubMed ID: 22441643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
    Kim JJ; Burger EA; Sy S; Campos NG
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.
    van Rosmalen J; de Kok IM; van Ballegooijen M
    BJOG; 2012 May; 119(6):699-709. PubMed ID: 22251259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
    Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ
    J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis.
    Georgalis L; de Sanjosé S; Esnaola M; Bosch FX; Diaz M
    Eur J Cancer Prev; 2016 Sep; 25(5):430-9. PubMed ID: 26375246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.
    Burger EA; Pedersen K; Sy S; Kristiansen IS; Kim JJ
    Br J Cancer; 2017 Sep; 117(6):783-790. PubMed ID: 28772279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
    Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
    Felix JC; Lacey MJ; Miller JD; Lenhart GM; Spitzer M; Kulkarni R
    J Womens Health (Larchmt); 2016 Jun; 25(6):606-16. PubMed ID: 27023044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
    Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
    BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model-based analysis.
    Portnoy A; Pedersen K; Sy S; Tropé A; Engesaeter B; Kim JJ; Burger EA
    Int J Cancer; 2024 Mar; 154(6):1073-1081. PubMed ID: 38088449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of cervical cancer screening with primary HPV testing for unvaccinated women in Sweden.
    Fogelberg S; Clements MS; Pedersen K; Sy S; Sparén P; Kim JJ; Burger EA
    PLoS One; 2020; 15(9):e0239611. PubMed ID: 32997696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching clinic-based cervical cancer screening programs to human papillomavirus self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women.
    Pedersen K; Portnoy A; Sy S; Hansen BT; Tropé A; Kim JJ; Burger EA
    Int J Cancer; 2022 Feb; 150(3):491-501. PubMed ID: 34664271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The health and economic effects of HPV DNA screening in The Netherlands.
    Berkhof J; Coupé VM; Bogaards JA; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ
    Int J Cancer; 2010 Nov; 127(9):2147-58. PubMed ID: 20112339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
    Kim JJ; Wright TC; Goldie SJ
    J Natl Cancer Inst; 2005 Jun; 97(12):888-95. PubMed ID: 15956650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.
    Kim JJ; Ortendahl J; Goldie SJ
    Ann Intern Med; 2009 Oct; 151(8):538-45. PubMed ID: 19841455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
    Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM
    Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol.
    Teixeira JC; Vale DB; Bragança JF; Campos CS; Discacciati MG; Zeferino LC
    BMC Public Health; 2020 Apr; 20(1):576. PubMed ID: 32345284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
    Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
    Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.